# retatrutide glp1 agonists

slug: retatrutide-glp1-agonists · https://miscsubjects.com/a/retatrutide-glp1-agonists · updated 2026-07-17T02:41:16.988Z

## Overview
Evidence is being populated by Grok web search.

## Sources

1. Efficacy of GLP-1 analog peptides, semaglutide, tirzepatide ... — https://pubmed.ncbi.nlm.nih.gov/41723268/
2. Efficacy and Safety of GLP-1 Receptor Agonists, Dual ... — https://pubmed.ncbi.nlm.nih.gov/40685589/
3. Efficacy and safety of retatrutide, a novel GLP-1, GIP, and ... — https://pubmed.ncbi.nlm.nih.gov/40291085/
4. Retatrutide-A Game Changer in Obesity Pharmacotherapy — https://pubmed.ncbi.nlm.nih.gov/40563436/
5. A Study of Retatrutide (LY3437943) in Participants With Obesity and Cardiovascular Disease (TRIUMPH-3) — https://clinicaltrials.gov/study/NCT05882045
6. Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes... (TRANSCEND-T2D-1) — https://pubmed.ncbi.nlm.nih.gov/42250575/
7. Retatrutide in type 2 diabetes mellitus and obesity: an overview — https://pubmed.ncbi.nlm.nih.gov/41785010/
8. Retatrutide and the Paradigm Shift in Multi-Hormonal ... — https://pubmed.ncbi.nlm.nih.gov/41545327/
9. Retatrutide And Lipid And Metabolite Profiles In Participants With Obesity With Or Without Type 2 Diabetes — https://pubmed.ncbi.nlm.nih.gov/42135195/
10. Triple Hormone Receptor Agonism: The Role of Retatrutide in Addressing Cardiovascular-Kidney-Metabolic (CKM) Syndrome: A Comprehensive Review — https://pubmed.ncbi.nlm.nih.gov/42108533/
11. Retatrutide Shows Multiple Metabolic Benefits in Diet-Induced Obese MASH Mouse and Hamster Models — https://pubmed.ncbi.nlm.nih.gov/41741376/
12. A Study of Retatrutide (LY3437943) in Participants With Obesity or Overweight (TRIUMPH-8) — https://clinicaltrials.gov/study/NCT07232719
13. A Study of Retatrutide (LY3437943) Compared to Tirzepatide (LY3298176) in Adults Who Have Obesity (TRIUMPH-5) — https://clinicaltrials.gov/study/NCT06662383
14. The First Triple Agonist for Antiobesity: Retatrutide — https://pubmed.ncbi.nlm.nih.gov/39724554/
15. Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial — https://pubmed.ncbi.nlm.nih.gov/38858523/
16. Effects of retatrutide on body composition in people with type 2 diabetes — https://pubmed.ncbi.nlm.nih.gov/40609566/
17. Retatrutide for the treatment of obesity, obstructive sleep apnea and knee osteoarthritis: Rationale and design of the TRIUMPH registrational clinical trials — https://pubmed.ncbi.nlm.nih.gov/41090431/
18. Efficacy and safety of triple hormone receptor agonist retatrutide for the management of obesity: a systematic review and meta-analysis — https://pubmed.ncbi.nlm.nih.gov/39817343/
19. Incretin triple agonist retatrutide (LY3437943) alleviates obesity-associated cancer progression — https://pubmed.ncbi.nlm.nih.gov/40094000/
20. Triple Agonism Based Therapies for Obesity — https://pubmed.ncbi.nlm.nih.gov/40741227/
21. A Study of Retatrutide (LY3437943) on Renal Function in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes — https://clinicaltrials.gov/study/NCT05936151
22. A Study of Retatrutide (LY3437943) Once Weekly in Participants Who Have Obesity or Overweight and Osteoarthritis of the Knee — https://clinicaltrials.gov/study/NCT05931367